The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

In a subset of patients with chronic lymphocytic leukemia (CLL) treated with targeted agents, such as ibrutinib, drug resistant subclones emerge. Here, the authors report on transcriptional changes in CLL patients treated with ibrutinib and identify early clonal shifts associated with evolution of r...

Full description

Saved in:
Bibliographic Details
Main Authors: Dan A. Landau, Clare Sun, Daniel Rosebrock, Sarah E. M. Herman, Joshua Fein, Mariela Sivina, Chingiz Underbayev, Delong Liu, Julia Hoellenriegel, Sarangan Ravichandran, Mohammed Z. H. Farooqui, Wandi Zhang, Carrie Cibulskis, Asaf Zviran, Donna S. Neuberg, Dimitri Livitz, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Jan A. Burger, Adrian Wiestner, Catherine J. Wu
Format: article
Language:EN
Published: Nature Portfolio 2017
Subjects:
Science
Q
Online Access:https://doaj.org/article/8cb0dbf9095d4ad38df29729f10e5da6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items